Evidence map›Paper›PMID 24932409›Full record

ArticleMedical sciences (Basel, Switzerland)2014

Characterization of Free and Porous Silicon-Encapsulated Superparamagnetic Iron Oxide Nanoparticles as Platforms for the Development of Theranostic Vaccines.

Charles M Lundquist, Christopher Loo, Ismail M Meraz, Jorge De La Cerda, Xuewu Liu, Rita E Serda

Open access · goldAbstract read
In one paragraph

Article in Medical sciences (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Charles M LundquistNanomedicine and Biomedical Engineering, The University of Texas School of Medicine, Houston, TX 77030, USA.
Christopher LooDepartment of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX 77030, USA.
Ismail M MerazDepartment of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX 77030, USA.
Jorge De La CerdaSmall Animal Imaging Facility, University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
Xuewu LiuDepartment of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX 77030, USA.
Rita E SerdaDepartment of Nanomedicine, Houston Methodist Research Institute, 6670 Bertner Ave, Houston, TX 77030, USA.
Houston Methodist · USThe University of Texas MD Anderson Cancer Center · US

Funding

Texas Center for Cancer NanomedicineU54CA151668 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FERRARI, MAURO · 2010 to 2014
$12.4M
NCI NIH HHS U54 CA151668
6 · The paper itself

Abstract

Tracking vaccine components from the site of injection to their destination in lymphatic tissue, and simultaneously monitoring immune effects, sheds light on the influence of vaccine components on particle and immune cell trafficking and therapeutic efficacy. In this study, we create a hybrid particle vaccine platform comprised of porous silicon (pSi) and superparamagnetic iron oxide nanoparticles (SPIONs). The impact of nanoparticle size and mode of presentation on magnetic resonance contrast enhancement are examined. SPION-enhanced relaxivity increased as the core diameter of the nanoparticle increased, while encapsulation of SPIONs within a pSi matrix had only minor effects on T2 and no significant effect on T2* relaxation. Following intravenous injection of single and hybrid particles, there was an increase in negative contrast in the spleen, with changes in contrast being slightly greater for free compared to silicon encapsulated SPIONs. Incubation of bone marrow-derived dendritic cells (BMDC) with pSi microparticles loaded with SPIONs, SIINFEKL peptide, and lipopolysaccharide stimulated immune cell interactions and interferon gamma production in OT-1 TCR transgenic CD8

Indexed as

adjuvantantigeniron oxidemagnetic resonanceporous siliconvaccine

Identifiers

PMID24932409
PMCPMC4057016
OpenAlexW1995660895

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.